IDN 6734
Latest Information Update: 27 Nov 2007
Price :
$50 *
At a glance
- Originator Idun Pharmaceuticals
- Class Small molecules
- Mechanism of Action Caspase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Myocardial infarction; Stroke
Most Recent Events
- 19 Apr 2005 Idun Pharmaceuticals has been acquired by Pfizer
- 11 Feb 2003 Data presented at the 75th Scientific Sessions of the American Heart Association [11/02] have been added to the Ischaemic Heart Disease pharmacodynamics section
- 14 May 2002 Preclinical trials in Stroke in USA (unspecified route)